Free Trial

ARS Pharmaceuticals (SPRY) News Today

ARS Pharmaceuticals logo
$14.98 +0.46 (+3.17%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$15.06 +0.07 (+0.50%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRY Latest News

ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Wall Street Zen to Sell
Wall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday.
ARS Pharmaceuticals, Inc. stock logo
Woodline Partners LP Purchases 133,276 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Woodline Partners LP grew its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 13.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,119,283 shares of the company's stock after buying an additional 133,276 shar
ARS Pharmaceuticals, Inc. stock logo
Northern Trust Corp Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Northern Trust Corp boosted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 5.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 478,153 shares of the company's stock after purchasing an a
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from Analysts
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned a consensus recommendation of "Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy re
ARS Pharmaceuticals, Inc. stock logo
Rafferty Asset Management LLC Increases Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Rafferty Asset Management LLC lifted its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 72.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,372 shares of the compa
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Raised by Wexford Capital LP
Wexford Capital LP lifted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 48.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 369,497 shares of the company's stock after acquiring an additional 121,150
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company cut its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 58.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,526 shares of the company's stock after selling 27,328 shares during the period. Th
ARS Pharmaceuticals, Inc. stock logo
FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now expects that the compa
Cantor Fitzgerald Has Weak Estimate for SPRY FY2025 Earnings
Q2 EPS Estimate for ARS Pharmaceuticals Reduced by Analyst
ARS Pharmaceuticals, Inc. stock logo
Leerink Partnrs Has Bearish Outlook for SPRY Q2 Earnings
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q2 2025 earnings estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the co
ARS Pharmaceuticals, Inc. stock logo
William Blair Brokers Lower Earnings Estimates for SPRY
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Stock analysts at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a report issued on Wednesday, May 14th. William Blair analyst L. Hanbury-Brown now expects that the company will earn ($0.44)
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Jacobs Levy Equity Management Inc.
Jacobs Levy Equity Management Inc. reduced its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 84.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 101,397 shares of the company's
ARS Pharmaceuticals, Inc. stock logo
Price T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Price T Rowe Associates Inc. MD trimmed its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 95.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,918 shares of the company's stock after selling
Equities Analysts Set Expectations for SPRY Q2 Earnings
ARS Pharmaceuticals, Inc. stock logo
Panoramic Capital LLC Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Panoramic Capital LLC bought a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 45,806 shares of the company's stock, valued at approximately $483,000. Several
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stake Lowered by Nextech Invest Ltd.
Nextech Invest Ltd. decreased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 936,729 shares of the company's stock after
ARS Pharmaceuticals, Inc. stock logo
Nicholas Investment Partners LP Sells 29,753 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Nicholas Investment Partners LP decreased its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 14.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,018 shares of the company's stock after selling
ARS Pharmaceuticals, Inc. stock logo
Miura Global Management LLC Has $1.79 Million Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Miura Global Management LLC cut its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 37.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 170,000 shares of the com
ARS Pharmaceuticals, Inc. stock logo
Balyasny Asset Management L.P. Purchases 322,423 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Balyasny Asset Management L.P. grew its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 1,431.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 344,941 shares of the company's stock after acquiring an additional 322,423 shares during the
ARS Pharmaceuticals's Earnings: A Preview
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Voya Investment Management LLC
Voya Investment Management LLC lifted its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 40.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 67,277 shares of the company's stock after purchasing an additional 19,
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by DAFNA Capital Management LLC
DAFNA Capital Management LLC lowered its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 40.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 88,790 shares of the company's s
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Deerfield Management Company L.P. Series C
Deerfield Management Company L.P. Series C lessened its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 5.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,514,657 shares of the co
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Ancora Advisors LLC
Ancora Advisors LLC lowered its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 82.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,000 shares of the company's stock after selling 29,000 shares
ARS Pharmaceuticals, Inc. stock logo
Alyeska Investment Group L.P. Acquires 1,128,724 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Alyeska Investment Group L.P. boosted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 903.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,253,724 shares of the company's stock after purch
ARS Pharmaceuticals, Inc. stock logo
Invesco Ltd. Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Invesco Ltd. reduced its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 84.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,988 shares of the company's stock after selling 105,623 shares during
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Marshall Wace LLP
Marshall Wace LLP cut its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 32.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 52,906 shares of the company's stock after selling 24,973 shares
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Holdings Lifted by Barclays PLC
Barclays PLC increased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 41.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,180 shares of the company's stock after acqui
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on Thursday
ARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-ars-pharmaceuticals-inc-stock/)
ARS Pharmaceuticals, Inc. stock logo
Tower Research Capital LLC TRC Has $481,000 Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Tower Research Capital LLC TRC lifted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 958.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,576 shares of the company's s
ARS Pharmaceuticals Has A Blockbuster Candidate
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from Analysts
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have been given an average recommendation of "Buy" by the six analysts that are presently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy ra
ARS Pharmaceuticals, Inc. stock logo
Raymond James Financial Inc. Invests $6.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 623,281 shares of the company's stock, valued at approximately $6,576,0
ARS Pharmaceuticals, Inc. stock logo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Trexquant Investment LP
Trexquant Investment LP trimmed its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 33.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,563 shares of the company's stock after selling 28,7
ARS Pharmaceuticals, Inc. stock logo
ExodusPoint Capital Management LP Buys Shares of 24,628 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
ExodusPoint Capital Management LP bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 24,628 shares of the company's stock, v
ARS Pharmaceuticals, Inc. stock logo
Vanguard Group Inc. Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
Vanguard Group Inc. grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 3.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,464,952 shares of the company's stock after purchasing an additi
Get ARS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.

SPRY Media Mentions By Week

SPRY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SPRY
News Sentiment

0.07

0.75

Average
Medical
News Sentiment

SPRY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SPRY Articles
This Week

29

5

SPRY Articles
Average Week

Get ARS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SPRY) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners